Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607225 | 0.89 | CCR3 (0.62) | CCR3SLC6A3SIGMAR1ACKR3TMEM97 | |
| SCHEMBL4604479 | 0.83 | SLC6A3 (0.48) | SLC6A3KMT2APRMT3 | |
| SCHEMBL4900572 | 0.81 | CCR3 (0.62) | CCR3SLC6A3SIGMAR1ACKR3TMEM97 | |
| SCHEMBL4605023 | 0.75 | CCR3 (0.57) | CCR3SLC6A3SIGMAR1ACKR3TMEM97 | |
| SCHEMBL27719387 | 0.72 | TMEM97 (0.60) | CCR3SIGMAR1ACKR3TMEM97KMT2A | |
| SCHEMBL13989527 | 0.71 | CCR3 (0.57) | CCR3 | |
| Hydrochloric Acid SCHEMBL4880358 | 0.71 | CCR3 (0.56) | CCR3 | |
| SCHEMBL4891368 | 0.69 | CCR3 (0.53) | CCR3SLC6A3SIGMAR1ACKR3TMEM97 | |
| SCHEMBL4604195 | 0.69 | CCR3 (0.62) | CCR3 | |
| SCHEMBL4604183 | 0.69 | GSK3A (0.52) | CCR3SIGMAR1ACKR3TMEM97KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | CCR3 1/4885SLC6A3 4291/4885SIGMAR1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.